Janux Therapeutics Strategy and Business Model

Executive Overview

Janux Therapeutics is a San Diego-based clinical-stage biotechnology company focused on cancer immunotherapies designed to be more selectively activated in tumors than in normal tissue. Founded in 2017, Janux is trying to address one of the core problems in T-cell engager and other potent immune-oncology modalities: strong anti-tumor activity is often constrained by systemic toxicity. Its core platforms are Tumor Activated T Cell Engagers, or TRACTr, and tumor-activated immunomodulators. As of 2024, Janux’s lead clinical programs included JANX007, a prostate-specific membrane antigen-targeted candidate for metastatic castration-resistant prostate cancer, and JANX008, an epidermal growth factor receptor-targeted candidate for solid tumors. Janux operates primarily from the United States and remains pre-commercial, so its economics are driven by R&D spending, collaboration revenue, and capital markets funding rather than product sales. In FY2024, Janux reported revenue of #N/A, reflecting collaboration activity rather than approved-product sales. Strategically, the company is a platform biotech: it is attempting to prove that tumor-activated protein engineering can create a better therapeutic window, support multiple pipeline assets, and attract high-value partnerships.

Janux Therapeutics at a Glance

Logo
Common name	Janux Therapeutics
Full legal name	Janux Therapeutics, Inc.
Headquarters	San Diego, California, United States
Ownership	Public company; no controlling shareholder disclosed in public filings reviewed through 2024
Ticker	JANX
Exchange	NASDAQ
Market Cap	$911.72M
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2017; initial platform build as an oncology protein-engineering company; initial public offering in 2021; Merck collaboration announced in 2023; lead clinical readouts advanced in 2024
Industry or industries	Biotechnology; oncology therapeutics; immuno-oncology
Key products or services	Tumor Activated T Cell Engagers (TRACTr), tumor-activated immunomodulator candidates, and selective discovery/development collaborations
Geographic footprint	U.S.-based R&D organization with outsourced manufacturing and multicenter clinical-development activities
Business segments as officially reported	One operating and reportable segment
Company website	https://www.januxrx.com

1. What Is the Strategy of Janux Therapeutics?

Based on Janux’s public filings and investor materials through 2024, the company’s strategy is best understood as a platform-driven attempt to improve the therapeutic window of potent cancer immunotherapies, especially in solid tumors where conventional T-cell engager approaches have often struggled.

1a. What is the winning aspiration of Janux Therapeutics?

Janux’s winning aspiration is to become a clinically validated oncology platform company built around tumor-activated biologics. In practical terms, “winning” means demonstrating that its engineered molecules can produce meaningful anti-tumor activity while reducing off-tumor toxicity relative to less selective immune activators. For a company at Janux’s stage, success is not yet defined by commercial scale; it is defined first by clinical proof of concept, then by expanding the pipeline, creating partnering value, and ultimately bringing one or more products toward approval.
1b. Where does Janux Therapeutics play?

Janux plays in oncology, specifically in tumor-activated protein therapeutics. Its initial focus has been solid tumors with validated targets such as prostate-specific membrane antigen and epidermal growth factor receptor. The company also plays in the biopharma partnering market, where large pharmaceutical companies seek differentiated immuno-oncology platforms and early pipeline assets. Janux is not trying to compete broadly across all cancer treatment categories; it is narrowing its field to targets and modalities where selective activation may confer an advantage.
1c. How does Janux Therapeutics plan to win?

Janux plans to win through molecular design rather than scale. Its thesis is that tumor-activated architectures can keep highly potent immune therapies relatively quiet in circulation and more active in the tumor microenvironment. If that thesis holds clinically, Janux could offer a better balance of efficacy and tolerability, which would matter in dose intensity, outpatient feasibility, combination use, and adoption in solid tumors. The company also appears to be using a dual-path model: retain economic upside in internal lead programs while using partnerships to validate the platform and extend funding.
1d. What capabilities must Janux Therapeutics have in place?

To execute this strategy, Janux needs strong protein engineering, translational oncology, preclinical pharmacology, chemistry, manufacturing, and controls, clinical development, and regulatory capabilities. It also needs vendor-management strength because much of the manufacturing and trial infrastructure is outsourced. Just as important are biomarker and dose-escalation capabilities, since the clinical case for tumor activation depends on showing both activity and manageable safety in humans.
1e. What management systems does Janux Therapeutics require?

Janux needs tight stage-gate portfolio management, rigorous safety governance, disciplined cash allocation, and strong alliance management. Because it is a pre-commercial biotech with a concentrated pipeline, management systems around program prioritization, clinical milestone tracking, intellectual property protection, and external partner oversight are critical. The company also needs decision rules for when to self-fund, when to partner, and when to stop lower-priority work to preserve capital for the highest-conviction assets.

2. What Are the Current Strategic Initiatives of Janux Therapeutics?

Janux’s publicly visible strategic agenda in 2024 centered on turning platform promise into clinical and partnering evidence.

Advance JANX007 in metastatic castration-resistant prostate cancer. JANX007 has been the company’s lead clinical value driver. The core task has been dose escalation, safety characterization, and the search for early efficacy signals that could validate the TRACTr approach in a high-value oncology setting.
Move JANX008 through early clinical development. JANX008 extends the platform into epidermal growth factor receptor-expressing solid tumors. Strategically, it matters because it tests whether Janux’s engineering approach is repeatable across targets rather than asset-specific.
Progress discovery and preclinical programs, including partnered work. Janux’s collaboration with Merck adds strategic importance beyond near-term economics: it helps validate the platform externally and broadens the number of shots on goal without Janux carrying all of the cost alone.
Build out tumor-activated immunomodulator programs. Janux has also described work beyond T-cell engagers. This matters because the broader the platform can be applied, the stronger the case that Janux is building a durable technology company rather than a two-asset pipeline.
Strengthen manufacturing and development readiness. For biologics companies, early clinical execution is not only about science; it is also about reliable drug supply, release testing, comparability, and a clinical-operations system that can support sequential studies.
Maintain financial flexibility. Janux’s strategy requires capital discipline. Management has had to balance pipeline breadth with the need to preserve runway long enough to generate meaningful clinical readouts.

3. What Is the Business Model of Janux Therapeutics?

Janux’s current business model is that of a pre-commercial platform biotech rather than a traditional pharmaceutical company.

What customers actually buy

Today, Janux’s economic counterparties do not buy approved medicines from the company. Instead, what a partner buys is access to Janux’s platform, program rights, and future development/commercialization options. If Janux eventually secures product approvals, future buyers would include providers, payors, and specialty oncology channels purchasing a differentiated biologic therapy.

Recurring or repeat-driven versus one-time economics

Current revenue is primarily collaboration-based, which typically mixes one-time upfront payments, development milestones, regulatory milestones, sales milestones, and possible future royalties. That makes revenue lumpy rather than recurring in a software-like sense. The most repeatable economic engine today is not sales; it is the company’s ability to generate additional attractive candidates and partnership opportunities.

How pricing power works

At Janux’s current stage, pricing power shows up mainly in deal negotiations, not product pricing. Stronger clinical data can improve Janux’s leverage in collaboration discussions. If the company eventually commercializes a differentiated oncology biologic, pricing power would depend on the degree of efficacy, safety, and convenience versus competing therapies.

Why the business mix matters

The mix between wholly owned programs and partnered programs is strategically important. Owned assets preserve more long-term upside but require more capital. Partnered assets lower funding pressure and validate the platform but share economics. For Janux, this mix is a core capital-allocation choice.

What drives margin and cash generation

Gross margin and operating margin are not yet the right lens for assessing Janux because the company has no approved product base. Its income statement is dominated by research and development expense, general and administrative expense, and the timing of collaboration revenue recognition. Cash generation currently depends on equity financing and partner payments rather than operations. If Janux reaches commercialization, biologics can carry attractive gross margins, but that remains prospective.

Revenue model

In plain terms, Janux’s revenue model today is collaboration and licensing based, with future optionality for direct product sales and royalties if its candidates advance successfully.

4. What Products and/or Services Does Janux Therapeutics Sell?

Janux does not currently sell an approved commercial drug. Its most important offerings are pipeline assets and platform capabilities.

JANX007. A prostate-specific membrane antigen-targeted Tumor Activated T Cell Engager being developed for metastatic castration-resistant prostate cancer. As of 2024, this was Janux’s flagship clinical program and the company’s clearest near-term proof-of-concept asset.
JANX008. An epidermal growth factor receptor-targeted Tumor Activated T Cell Engager being developed for solid tumors. Strategically, this program is important because it extends the platform beyond a single target and tumor type.
TRACTr platform programs. Janux’s broader Tumor Activated T Cell Engager platform is intended to generate additional oncology candidates, including partnered assets.
Tumor-activated immunomodulator programs. These preclinical efforts broaden Janux beyond T-cell engagers into other immune-activation approaches where tumor selectivity could matter.
Collaboration value. For pharmaceutical partners, Janux effectively offers access to a differentiated discovery and engineering platform plus specific development-stage or discovery-stage programs.

From a strategic standpoint, JANX007 and JANX008 appear to carry the greatest immediate value because they are the programs most likely to determine whether the platform can create clinical and financial leverage.

5. What Are the Key Competitors or Peers of Janux Therapeutics?

For Janux, competition is best viewed at the modality, target, and platform level rather than as a simple company-versus-company contest. Its relevant peers include established bispecific developers, oncology biologics companies, and firms working on conditionally activated therapeutics.

Amgen. A major benchmark in T-cell engagers through its BiTE platform and commercial experience. Amgen demonstrates what scaled T-cell engager development and commercialization can look like.
Regeneron. A large-cap biotechnology company with deep antibody-engineering capabilities, significant bispecific development experience, and broad oncology resources.
Roche / Genentech. A major oncology incumbent with a broad biologics toolkit and the capital to compete aggressively in targeted and immune-oncology combinations.
Xencor. A close technology-oriented peer in engineered antibodies and bispecific formats, with a business model that also mixes internal development and partnerships.
Merus. A bispecific antibody company with meaningful solid-tumor ambitions and platform credibility, making it a relevant peer for investors comparing emerging oncology biologics platforms.
MacroGenics. Another antibody-engineering and oncology biologics peer with deep experience in multispecific formats and translational development.
CytomX Therapeutics. One of the more relevant strategic peers on the idea of conditional activation in tumors. CytomX is not identical to Janux, but both are trying to improve therapeutic index through masking or tumor-selective activation logic.
Sanofi via Amunix. Amunix brought Sanofi a set of masked T-cell engager and pro-cytokine technologies, making it relevant in the subset of oncology where conditional activation is the core design problem.
AbbVie / Genmab and other large bispecific developers. These companies are not perfect one-for-one peers, but they shape physician expectations, regulatory precedent, and partnering alternatives in the broader bispecific oncology market.

Janux can also face competition from companies targeting the same tumor antigens or patient populations, even when the underlying modality differs.

6. What Is the Marketing Strategy of Janux Therapeutics?

Janux does not yet have a conventional commercial marketing strategy because it has no approved products. Its current “marketing” is really a mix of scientific communication, business development, investor communication, and clinical-site engagement.

Scientific marketing. Conference presentations, clinical updates, publications, and interactions with key opinion leaders are central. In biotech, data visibility is often the most important form of marketing.
Partner-facing positioning. Janux needs to communicate why its platform is differentiated enough to justify collaboration economics. That makes business development messaging strategically important.
Clinical-community engagement. Relationships with investigators and trial sites support enrollment, credibility, and future product positioning in oncology.
Capital-markets communication. Because Janux is pre-commercial, investor confidence influences access to funding. Public communication around data, strategy, and runway therefore matters more than consumer or trade advertising.

Brand marketing is not a major differentiator today. Scientific credibility is.

7. What Are the Key Customer Segments of Janux Therapeutics?

Janux’s customer picture is unusual because the company is still pre-commercial.

Current economic customers: pharmaceutical partners. Today, the clearest revenue-generating customer segment is large biopharma companies that license, collaborate on, or option Janux programs and platform capabilities.
Future prescribers and treatment centers. If Janux brings a therapy to market, the relevant users would be oncologists, urologists, academic cancer centers, and community oncology practices treating patients in its chosen indications.
Future payors. Commercial insurers, Medicare-related reimbursement channels, and other payors would become crucial gatekeepers if Janux commercializes a product.
Patients. End demand ultimately comes from cancer patients, but the economic buying process in oncology is mediated by physicians, institutions, and payors.

At present, Janux is not diversified across many paying customer groups. Revenue concentration is high because collaboration counterparties matter far more than product end-markets today.

8. What Is the Sales Model of Janux Therapeutics?

Today, Janux has no traditional product-sales model. Its current go-to-market approach is best described as direct partnering and program development.

Current model. Senior management and business development teams pursue collaboration agreements directly with pharmaceutical companies. That is the company’s de facto sales channel.
No broad distribution structure yet. Janux does not currently rely on wholesalers, retail pharmacy, field promotion, or distributor networks because it has no marketed product.
Clinical channel instead of commercial channel. In the near term, Janux reaches the market through investigators, trial sites, and scientific congresses rather than through a salesforce.
Future commercial model. If a program succeeds, Janux could either build a focused specialty-oncology commercial team for the United States or partner broader geographies and channels. That future structure is still an inference, not an announced plan.

This channel structure matters because it affects capital needs. A partnership-led model can reduce fixed commercial overhead, while a self-commercialization model preserves more economics but requires more investment.

9. In What Geographies Does Janux Therapeutics Operate?

Janux’s operational footprint is concentrated rather than globally distributed. The company is headquartered in San Diego, California, which serves as the center of its research, management, and corporate activity. As of public disclosures through 2024, Janux did not present itself as a multinational commercial operator with a large foreign office network.

Its geographic reach comes mainly through outsourced vendors, multicenter clinical trials, and partnering relationships rather than owned international infrastructure. Manufacturing, testing, and trial execution can involve third parties in multiple locations, but Janux itself remains primarily U.S.-based. That concentration is typical for a clinical-stage biotech and likely helps contain overhead while the company is still proving its lead assets.

10. Who Are the Owners of Janux Therapeutics?

Janux is a publicly traded company listed on Nasdaq. As of public filings reviewed through 2024, the company did not disclose a controlling shareholder. Its shareholder base has largely consisted of institutional investors, specialist healthcare funds, venture-related holders associated with its early development, and management insiders. Affiliates of Avalon Ventures, Janux’s founding incubator, have historically been notable holders. Because ownership in small-cap biotech can change materially after financings and data releases, the latest proxy statement and Schedule 13 filings are the best sources for current holders above 5%.

11. How Is Janux Therapeutics Organized?

Janux is organizationally simple compared with a commercial pharmaceutical company. Legally and for financial reporting purposes, it has one operating and reportable segment. Practically, the company appears to be organized around core functional groups such as discovery biology, protein engineering, translational science, clinical development, regulatory affairs, chemistry, manufacturing, and controls, and corporate functions.

The operating model is program-centric: shared platform capabilities support multiple candidates, while individual program teams drive target-specific development decisions. Because Janux is still pre-commercial, it does not need the multiple regional sales organizations, brand franchises, or product divisions seen at larger drug companies.

12. How Does Janux Therapeutics Operate?

On a day-to-day basis, Janux operates like a focused development-stage biotech built around a core engineering platform.

Discovery and design. Internal teams select targets, engineer molecules, and optimize constructs intended to balance potency, selectivity, and manufacturability.
Preclinical validation. Janux runs in vitro and in vivo work to understand binding, activation, pharmacology, safety signals, and differentiation versus less selective approaches.
External manufacturing. Like many companies at its size, Janux relies heavily on contract development and manufacturing organizations for biologics production, fill-finish, testing, and clinical supply.
Clinical development. The company designs early-stage trials, manages investigators and contract research organizations, monitors safety, and interprets translational and efficacy data.
Portfolio and partnering decisions. Management then uses those data to decide which programs to advance internally, which to partner, and how broadly to expand the platform.

The operational bottlenecks are typical for this type of company: manufacturing reliability, patient enrollment, assay turnaround, regulatory documentation, and the challenge of proving a safety-and-efficacy advantage early enough to justify continued investment.

13. What Are the Growth Opportunities for Janux Therapeutics?

Janux’s most plausible growth opportunities stem from platform validation and smart capital allocation rather than from near-term volume growth.

Clinical proof of concept in JANX007. Stronger data in prostate cancer would materially improve the value of the lead program and the credibility of the broader platform.
Expansion of JANX008 and other solid-tumor programs. If Janux can show that tumor activation works across multiple targets, it becomes more attractive as both a drug developer and a partnering platform.
Pipeline multiplication. Additional TRACTr and tumor-activated immunomodulator candidates can create more shots on goal without changing the core technical thesis.
Partnerships and licensing. Janux can generate non-dilutive capital, external validation, and geographic or program-specific reach through additional collaborations.
Indication expansion. If a lead asset works in one setting, Janux could eventually explore earlier lines of therapy, combinations, or adjacent tumor types.
Future commercialization. A successful internal launch in a focused oncology indication could create a much larger economic step-up than milestone revenue alone.

The main constraints are equally clear: clinical failure risk, manufacturing complexity, intense competition in oncology biologics, regulatory uncertainty, and the need to keep financing pace with development timelines.

14. What Is the History of Janux Therapeutics?

Janux was founded in 2017 in San Diego by David Campbell and colleagues associated with the Avalon Ventures ecosystem. From the beginning, the company’s identity was tied to a platform idea rather than to a single drug asset: engineer highly potent immune-oncology biologics so they are more selectively activated in tumors.

In its early years, Janux built out the scientific platform and raised private capital to move from concept to pipeline. The company completed its initial public offering in 2021, giving it the balance-sheet capacity to advance internal programs into the clinic. A major strategic milestone came in 2023, when Janux announced a collaboration with Merck involving discovery-stage TRACTr programs. By 2024, Janux had shifted from being judged mainly on platform theory to being judged increasingly on human data, especially from JANX007 and the broader progress of its early clinical pipeline.

15. What Are the Key Suppliers to Janux Therapeutics?

Suppliers matter materially to Janux because it is a clinical-stage biologics company with substantial outsourcing. The most important supplier categories are:

Contract development and manufacturing organizations. These vendors produce clinical-grade biologic drug substance and drug product and often support scale-up and process development.
Analytical testing and quality vendors. Release testing, stability testing, comparability work, and other quality-control activities are critical for regulatory compliance.
Contract research organizations. CROs support study management, data handling, biostatistics, monitoring, and regulatory operations.
Preclinical service providers. Toxicology, pharmacology, and assay-development partners are important in moving candidates toward the clinic.
Clinical logistics and specialty distribution providers. Even before commercialization, trial materials need cold-chain handling, labeling, and site delivery.

Supplier structure matters strategically because timelines in biotech are often determined by vendor capacity, batch success, and documentation quality as much as by scientific ambition.

16. How Does the Supply Chain of Janux Therapeutics Function?

Janux’s supply chain is not a retail-style network; it is a development-stage biologics supply chain centered on small-batch production, quality control, and clinical-trial delivery.

Sourcing. Janux relies on specialized inputs, biologics manufacturing materials, laboratory reagents, and external scientific services.
Manufacturing. Drug substance and fill-finish activities are largely outsourced, which makes technology transfer, capacity booking, and process consistency important management tasks.
Testing and release. Analytical release, sterility, potency, and stability testing are mandatory before clinical product can be shipped.
Clinical distribution. Product then moves through controlled logistics to trial sites, often under temperature-sensitive conditions and tight chain-of-custody requirements.
Feedback loop. Data from each batch, study cohort, and protocol amendment feeds back into process changes, forecasting, and vendor planning.

Reliability matters more than sheer scale at this stage. A single manufacturing or release delay can affect dosing schedules, data timing, and investor expectations.

17. What Are the Key Assets of Janux Therapeutics?

For Janux, the key assets are mostly intellectual and financial rather than physical.

Lead clinical assets. JANX007 and JANX008 are the most visible value-bearing assets because they can generate proof of concept.
Platform intellectual property and know-how. Janux’s tumor-activated engineering approach is the foundation of its strategic differentiation.
Preclinical pipeline. Additional candidates matter because they extend option value beyond any single trial outcome.
Cash and investments. In biotech, balance-sheet strength is itself a strategic asset because it determines how long management can keep learning before returning to the market for capital.
Partnerships. The Merck collaboration is an asset in both economic and signaling terms.
Scientific team and San Diego R&D base. The ability to design, interpret, and refine complex biologics programs is a core intangible asset.

Janux is not asset-heavy in the sense of owning large plants or commercial infrastructure. Its value is concentrated in molecules, data, patents, and liquidity.

18. What Is the Technology Strategy of Janux Therapeutics?

Technology is central to Janux’s strategy; it is not just an internal enabler. The company’s core bet is that intelligent protein engineering can solve a biological selectivity problem that has limited broader use of potent immune activators in solid tumors.

Its technology strategy appears to have three layers. First, create modular tumor-activated architectures that can be retargeted to different tumor antigens. Second, use that architecture to widen the therapeutic window by reducing activation outside the tumor environment. Third, turn the platform into a repeatable development engine rather than a one-off scientific trick. If Janux can do that, the platform becomes strategically more valuable than any single asset.

This is a technology strategy built around repeatability, selectivity, and translational proof. The key test is whether those engineering advantages remain visible once candidates are exposed to human dosing, manufacturing constraints, and real-world tumor biology.

19. What Is the R&D Strategy of Janux Therapeutics?

Janux’s R&D strategy is to invest in a focused number of high-conviction oncology programs that can validate the platform while preserving the flexibility to generate follow-on assets. That is a common but difficult balance in biotech: too few programs create binary risk, while too many can overwhelm cash and management bandwidth.

Platform-led candidate generation. Janux appears to use a common engineering logic across programs, which should improve learning transfer from one asset to the next.
Translational emphasis. Early clinical development is not only about tumor response; it is also about understanding safety, activation, pharmacodynamics, and biomarker signals that either support or weaken the core scientific thesis.
Stage-gated spending. The company’s structure suggests a need to spend heavily where proof points are near and more selectively on earlier-stage assets.
Externalized execution where useful. Janux can keep internal focus on design and decision-making while using outside organizations for flexible development capacity.

In effect, Janux’s R&D strategy is to make each clinical program do double duty: advance a specific asset and validate the broader platform.

20. What Is the Finance Strategy of Janux Therapeutics?

Janux’s finance strategy is typical of a clinical-stage biotech but still strategically important. The company is not managing for near-term earnings; it is managing for runway, optionality, and milestone creation.

Prioritize liquidity. Cash runway is central because clinical development timelines are long and uncertain.
Fund value-inflecting programs first. Lead assets that can change the company’s valuation or partnering leverage should command the largest share of capital.
Use partnerships as non-dilutive support. Collaborations can help fund research, validate the platform, and reduce sole-funding pressure.
Maintain operating discipline. For a company without product revenue, controlling fixed-cost expansion is as important as raising capital.
No mature-company cash return priorities. Dividend policy and buybacks are not relevant; reinvestment and balance-sheet durability are.

For Janux, finance is inseparable from strategy. The company needs enough capital to reach meaningful clinical readouts without diluting itself so aggressively that future value capture becomes harder.

21. How Companies Like Janux Therapeutics Leverage Independent Consultants through Umbrex

Umbrex has grown a global community of more than 8,000 independent management consultants based in more than 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top consulting firms. Companies like Janux Therapeutics engage Umbrex when they need that level of problem-solving skill but do not need a full consulting team with all the overhead. Umbrex consultants work across Strategy, Operations, Organization, Marketing, Sales, Finance, Technology, ERP, and AI. For a company like Janux, the most relevant use cases are targeted, high-stakes projects tied to pipeline decisions, partnering, clinical operations, and commercialization planning.

Pipeline prioritization and capital-allocation review across JANX007, JANX008, preclinical immunomodulator work, and partnered assets.
Indication-sequencing strategy for deciding where Janux should concentrate development resources first and which expansions to defer.
Competitive landscape and war-gaming focused on T-cell engagers, conditionally activated biologics, and target-level oncology competition.
Partnering strategy support for regional licensing, co-development options, or additional platform collaborations.
Alliance-management design for collaborations such as the Merck relationship, including governance, escalation paths, and milestone tracking.
Clinical-operations improvement projects covering trial-start-up bottlenecks, site activation, enrollment analytics, and vendor oversight.
Chemistry, manufacturing, and controls operating-model work such as contract development and manufacturing organization selection, vendor scorecards, tech-transfer planning, and supply-risk mapping.
Commercial-readiness planning for a potential first launch, including specialty-sales sizing, medical-affairs design, and market-access scenarios.
Board-ready finance and scenario modeling around cash runway, financing choices, portfolio tradeoffs, and milestone-based budgeting.
AI-enabled knowledge workflows for scientific intelligence, competitor monitoring, and internal decision support without requiring a large in-house analytics build.